Forte Biosciences (FBRX) Long-Term Deferred Tax (2017 - 2019)
Forte Biosciences (FBRX) posted quarterly Long-Term Deferred Tax of $53.8 million for Q4 2019, up 28.1% year-over-year from $42.0 million in Q4 2018, and up 28.1% quarter-over-quarter from $42.0 million in Q4 2018.
Forte Biosciences (FBRX) Long-Term Deferred Tax (2017 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has reported Long-Term Deferred Tax for 3 consecutive years, with $53.8 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Long-Term Deferred Tax rose 28.1% year-over-year to $53.8 million; the TTM figure through Dec 2019 stood at $53.8 million (up 28.1% YoY), while the FY2019 annual figure was $53.8 million, up 28.1% from the prior year.
- Long-Term Deferred Tax grew to $53.8 million in Q4 2019 per FBRX's latest filing, from $42.0 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $53.8 million in Q4 2019 and bottomed at $31.8 million in Q4 2017.
- Historically, Long-Term Deferred Tax has averaged $42.5 million across 3 years, with a median of $42.0 million in 2018.
- Annual changes were most pronounced in 2018 — Long-Term Deferred Tax jumped 32.08% — and 2019, when it increased 28.1%.
- Forte Biosciences' Long-Term Deferred Tax stood at $31.8 million in 2017, then jumped by 32.08% to $42.0 million in 2018, then increased by 28.1% to $53.8 million in 2019.
- Business Quant data shows FBRX's Long-Term Deferred Tax at $53.8 million in Q4 2019, $42.0 million in Q4 2018, and $31.8 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 53.80 Mn |
| Dec 31, 2018 | 42.00 Mn |
| Dec 31, 2017 | 31.80 Mn |